| LBCTR2019121371 | CLDK378A2303 | ASCEND 5: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib | Interventional | Complete | 27/12/2019 |
| LBCTR2019121369 | CLDK378A2112 | ASCEND 8-Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | Interventional | Complete | 27/12/2019 |
| LBCTR2022035012 | BIO-2021-0404 | Changes of Resting Metabolic Rate in University Athletes | Changes of Resting Metabolic Rate in University Athletes | Interventional | Pending | 14/03/2022 |
| LBCTR2019070266 | CLCZ696B2319E1 | CLCZ696B2319E1 Open Label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With Heart Failure (HF). | A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 | Interventional | Complete | 17/07/2019 |
| LBCTR2019010182 | CLDK378A2X01B | CLDK378A2X01B Roll over study in patients with ALK postive malignancies | An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib | Interventional | Complete | 09/01/2019 |
| LBCTR2019121368 | CINC280A2201 | Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer | A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) | Interventional | Complete | 25/12/2019 |
| LBCTR2020094590 | CMBG453B12301 | CMBG453B12301 Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | Interventional | Complete | 18/09/2020 |
| LBCTR2023065392 | CEHDF2110 | Comparison of the impact of two NEurofeedback EEG protocols on the perception and threshold of experimental pain in healthy subjects | Physiological and validation study in healthy subjects of the effect of two Neurofeedback protocols on acute pain - clinical trial. | Interventional | Recruiting | 29/06/2023 |
| LBCTR2024095653 | H.pylori-2016-001 | Comparison of Two Treatment Regimens for Helicobacter pylori Eradication in Lebanon | A Randomized Prospective and Crossover Study Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population | Observational | Complete | 16/09/2024 |
| LBCTR2019010184 | CLEE011A2404 | COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease | COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease | Interventional | Complete | 11/01/2019 |